Un-audited financial Results for the quarter ended 30.06.2025 are enclosed.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech reported a strong turnaround in Q1 FY26 with revenue from operations of Rs. 579.77 lakhs, up about 43% from Rs. 406.41 lakhs in Q1 FY25. The company swung to a profit of Rs. 23.60 lakhs from a loss of Rs. 52.81 lakhs in the same quarter last year, with EPS of Rs. 0.89 versus negative Rs. 1.83 earlier. Total revenue including other income stood at Rs. 588.86 lakhs, while total expenses were Rs. 565.26 lakhs. For the full FY25, the company had reported a loss of Rs. 179.81 lakhs on revenue of Rs. 1,355.83 lakhs. The statutory auditor, Rajiv Udai & Associates, issued an unmodified limited review report.
The sharp YoY revenue jump and return to profitability in Q1 FY26 signal improving business momentum after a loss-making FY25. Shareholders may view this positively, though the small base size and full-year FY25 loss mean sustainability of the recovery remains to be seen.